您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > SCH772984 HCl
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
SCH772984 HCl
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
SCH772984 HCl图片
CAS NO:942183-80-4
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍

化学性质

Physical AppearanceA solid
StorageStore at -20°C
M.Wt624.17
Cas No.942183-80-4 (free base)
FormulaC33H34ClN9O2
Solubility≥23.5 mg/mL in H2O with gentle warming; insoluble in EtOH; ≥16.27 mg/mL in DMSO
Canonical SMILESO=C(N1CCN(C2=CC=C(C3=NC=CC=N3)C=C2)CC1)CN4CC[C@@](/C(O)=N/C5=CC(C(C6=CC=NC=C6)=NN7)=C7C=C5)([H])C4.Cl
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

SCH772984 HCl is a specific inhibitor of extracellular signal-regulated kinase 1/2 (ERK1/2), with IC50 values of 4 nM and 1 nM, respectively [1].

ERK1/2 is a mitogen-activated protein kinase (MAPK) which is involved in the development of various cancers, especially the ones withBRAF orRAS mutations. Phospho-ERK reactivation in cancer cells is associated with resistance to BRAF and MEK inhibitors [1].

InBRAFV600E-mutant human melanoma cell line LOXIMV1 (LOX), SCH772984 at 0 ~ 300 nM inhibited phosphorylation of the ERK substrate p90 ribosomal S6 kinase in a dose-dependent manner. SCH772984 also reduced phosphorylation of residues in the activation loop of ERK itself. In addition, for approximately 88% and 49% ofBRAF-mutant orRAS-mutant tumor lines, SCH772984 exhibited antiproliferative activity with EC50 values < 500 nM. SCH772984 effectively inhibited MAPK signaling and cell proliferation even in tumor cells resistant to concurrent treatment with BRAF and MAP-ERK kinase (MEK) inhibitors [1].

In female nude mice bearing human LOXBRAFV600E tumors, SCH772984 (12.5, 25, 50 mg/kg, i.p., b.i.d., for 14 days) induced tumor regressions in a dose-dependent manner, and 98% tumor regression was achieved at the largest dose [1].

Reference:

[1]. Morris E J, Jha S, Restaino C R, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discovery, 2013, 3(7): 742-750.

试验操作

Cell experiment:[1]

Cell lines

BRAFV600E-mutant human melanoma cell line LOXIMV1 (LOX)

Reaction Conditions

0 ~ 300 nM SCH772984 for 24 h incubation

Applications

SCH772984 inhibited phosphorylation of the ERK substrate p90 ribosomal S6 kinase in a dose-dependent manner. SCH772984 also reduced phosphorylation of residues in the activation loop of ERK itself, a modification catalyzed by the ERK-activating kinases, MEK 1 and MEK 2.

Animal experiment:[1]

Animal models

Female nude mice bearing human LOXBRAFV600Etumors

Dosage form

12.5, 25, 50 mg/kg

Twice daily (b.i.d.) by intraperitoneal route (i.p.) for 14 days

Applications

In female nude mice bearing human LOXBRAFV600Etumors, SCH772984 (12.5, 25, 50 mg/kg, i.p., b.i.d., for 14 days) induced tumor regressions in a dose-dependent manner, and 98% tumor regression was achieved at the largest dose.

Note

The technical data provided above is for reference only.

References:

1. Morris E J, Jha S, Restaino C R, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discovery, 2013, 3(7): 742-750.